Financials
Financial year 2026
3SPHARMA from Lubbeek, company number BE0817889449, closed financial year 2026 with a result of € 17,346 after tax. For that financial year 3SPHARMA recorded a gross margin of € 144,974 and equity of € 380,122. Compared with financial year 2025, the result moved from € 74,387 to € 17,346. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 30, 2026.
€ 380,122
▲ 5% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 17,346
▼ 77% vs 2025
Profit after tax over the fiscal year.
€ 320,381
▲ 14% vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € 359,662.
People and assets in 2026
€ 66,663
▲ 37% vs 2025
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,809
▲ 17% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
€ 151,785
▼ 23% vs 2025
€ 46,119 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 96,457
▲ 76% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 18,019
▼ 25% vs 2025
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 158,101 | € 171,685 | € 203,724 | € 144,974 | ▼ 29% |
| Profit after taxes | € 54,055 | € 55,785 | € 74,387 | € 17,346 | ▼ 77% |
| Equity | € 232,603 | € 288,388 | € 362,775 | € 380,122 | ▲ 5% |
| Total debts | € 439,334 | € 364,897 | € 321,008 | € 310,694 | ▼ 3% |
| Cash | € 262,181 | € 196,786 | € 281,399 | € 320,381 | ▲ 14% |
| Retained profit | € 214,003 | € 267,928 | € 342,315 | € 359,662 | ▲ 5% |
| Bank debt | € 291,458 | € 244,489 | € 197,393 | € 151,785 | ▼ 23% |
| Balance sheet total | € 671,937 | € 653,285 | € 683,783 | € 690,815 | ▲ 1% |
Key figures of 3SPHARMA, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to 3SPHARMA?
What happened at 3SPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 17,346 (▼ 77% vs 2025). Source: NBB ↗
- New establishment in Lubbeek. KBO
- Dries Poppe became a director. NBB
- Martine Schoolmeesters became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 54,055 profit in 2023 to € 17,346 profit in 2026.
Paid € 99,031 in corporate taxes since 2023.
Best year ever: 2025, with € 74,387 profit.
Management
Behind 3SPHARMA are Dries Poppe and Martine Schoolmeesters.
Directors
According to the 2026 annual accounts
Dries Poppe
Director
since 2009
Martine Schoolmeesters
Associate
since 2009
Establishments
Establishment units
Physical locations of this company
Hertogenlaan(LIN) 35
3210 Lubbeek
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0817.889.449
- VAT number
- BE 0817.889.449
- Registered office
- Hertogenlaan(LIN) 35, 3210 Lubbeek
- Names & denominations
- 3SPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 August 2009
- Peppol
- Active · Active since 27 Nov 2025
- Activities · NACE
Detailhandel in farmaceutische producten